Free Trial

Heron Therapeutics (NASDAQ:HRTX) Raised to "Buy" at StockNews.com

Heron Therapeutics logo with Medical background
Remove Ads

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.

Separately, Needham & Company LLC reissued a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday.

View Our Latest Research Report on Heron Therapeutics

Heron Therapeutics Trading Up 13.8 %

NASDAQ HRTX traded up $0.31 on Friday, hitting $2.55. The company's stock had a trading volume of 2,694,384 shares, compared to its average volume of 1,819,324. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The firm has a market cap of $387.84 million, a P/E ratio of -14.17 and a beta of 1.60. The company's 50-day simple moving average is $1.70 and its 200 day simple moving average is $1.71.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million during the quarter, compared to analysts' expectations of $37.37 million. On average, research analysts forecast that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Heron Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its position in shares of Heron Therapeutics by 21.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company's stock worth $90,000 after buying an additional 7,927 shares during the period. Principal Financial Group Inc. grew its holdings in Heron Therapeutics by 456.5% in the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock worth $204,000 after purchasing an additional 84,205 shares during the period. GSA Capital Partners LLP increased its stake in shares of Heron Therapeutics by 18.4% during the third quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company's stock valued at $1,020,000 after purchasing an additional 79,680 shares in the last quarter. King Wealth Management Group increased its stake in shares of Heron Therapeutics by 52.3% during the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Heron Therapeutics during the third quarter valued at approximately $72,000. Institutional investors own 80.01% of the company's stock.

Heron Therapeutics Company Profile

(Get Free Report)

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Articles

Should You Invest $1,000 in Heron Therapeutics Right Now?

Before you consider Heron Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.

While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads